Abcam the most awarded company at 2022 industry awards
PR95172
CAMBRIDGE, England, March 25, 2022 /PRNewswire=KYODO JBN/ --
Abcam (https://corporate.abcam.com/) (AIM:ABC); (NASDAQ:ABCM), today announced
that it has received six recognitions from CiteAb at their annual industry
awards (https://www.citeab.com/awards/2022), the highest of any participant
evaluated this year. This record number of acknowledgments follows a year of
substantial investment for Abcam to enable life sciences researchers from
academia and industry to advance discoveries and deliver faster breakthroughs.
First and foremost, Abcam was recognized for its initiatives to improve
standards in the reagent industry. Its "Recombinant Multiclonal" range, which
combines the benefits of recombinant monoclonal and polyclonal antibodies, was
awarded "Innovation of the Year" by a panel of experts while Abcam was highly
commended in the "Recombinant Antibody Supplier of the Year" category. The
Company also won the "Supplier Succeeding in KO Validation" award for its
antibody validation program
(https://www.abcam.com/primary-antibodies/knockout-validation). All three
awards demonstrate Abcam's commitment to continually improving scientific
reproducibility in life sciences, which benefits the research community and
society globally.
Prof. Giovanna Roncador, Head of the Monoclonal Antibodies Unit/Biotechnology
Program at the Spanish National Cancer Research Center (CNIO), Founder and
Chair of EuroMabNet and recipient of the 2022 CiteAb award for "Significant
Individual Impact
(https://www.citeab.com/awards/2022/award-for-significant-individual-impact)"
said: "As a cancer researcher and antibody engineer, I firmly believe that
advancing science goes hand in hand with improving standards for reagent
quality. I am delighted but not surprised to see Abcam's success in the CiteAb
Awards, as, this year again, they have taken a number of strides forward to
deliver the scientific community the tools they need for success."
Dr. Alejandra Solache, SVP Research and Development at Abcam and recipient of
the 2021 CiteAb award for "Significant Individual Impact
(https://corporate.abcam.com/13452-2/)" commented: "We are excited to see our
dedication to delivering higher standards being acknowledged as we continually
look for new ways in which we can break barriers and set new industry standards
for improving reproducibility in science. Thank you to CiteAb, the judging
panels and the researchers with whom we share the same passion to drive life
sciences forward."
Finally, this year's CiteAb awards also recognize Abcam's effort to address the
growing demand of the sector for high-performance, reproducible, off-the-shelf
assays with the acquisition of BioVision for $340M
(https://corporate.abcam.com/bvii/). Offering a platform for greater innovation
and increasing access to biochemical assays and cellular assays, the deal is
recognized for its potential to lay the foundations for future positive impact
across the life sciences sector.
Abcam's 2022 full list of recognitions include:
Acquisition of the Year
(https://www.citeab.com/awards/2022/acquisition-of-the-year) – Winner
(BioVision)
Innovation of the Year (https://www.citeab.com/awards/2022/innovation-award) –
Winner (Recombinant Multiclonal range)
Supplier Succeeding in KO validation
(https://www.citeab.com/awards/2022/supplier-succeeding-in-ko-validation) –
Winner
Recombinant Antibody Supplier of the Year
(https://www.citeab.com/awards/2022/recombinant-antibody-supplier-of-the-year)
- Highly Commended
Supplier Succeeding in Cancer Research
(https://www.citeab.com/awards/2022/supplier-succeeding-in-cancer-research) -
Highly Commended
Supplier Succeeding in Sars-Cov-2 research
(https://www.citeab.com/awards/2022/supplier-succeeding-in-sars-cov-2-research)
- Highly Commended
About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes
high-quality biological reagents and tools that are crucial to research, drug
discovery and diagnostics. Working across the industry, the Company supports
life scientists to achieve their mission, faster.
Abcam partners with life sciences organizations to co-create novel binders for
use in drug discovery, in vitro diagnostics and therapeutics, driven by the
Company's proprietary discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the
global understanding of biology and causes of disease, which enables new
treatments and improved health. The Company's pioneering data-sharing approach
gives scientists increased confidence in their results by providing validation,
user comments and peer-reviewed citations for its 90,000 products.
With a direct presence in America, Asia and Europe, many of Abcam's over
1,700-strong team are located in the world's leading life sciences research
hubs, complementing a global network of service and support.
To find out more, please visit www.abcam.com (http://www.abcam.com/) and
corporate.abcam.com (https://corporate.abcam.com/)
Logo - https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg
SOURCE: Abcam
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。